AnaptysBio (FRA:AN6) DeferredTaxAndRevenue: €0.0 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

AnaptysBio Inc FRA:AN6

What is AnaptysBio DeferredTaxAndRevenue?

AnaptysBio FRA:AN6 -0.44% 44 DeferredTaxAndRevenue is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:AN6 with a GF Score™ of 44/100. The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

AnaptysBio's current deferred tax and revenue for the quarter that ended in Mar. 2026 was €0.0 Mil.

AnaptysBio DeferredTaxAndRevenue Related Terms

AnaptysBio DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for AnaptysBio's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio DeferredTaxAndRevenue Chart

AnaptysBio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

DeferredTaxAndRevenue

Get a 7-Day Free Trial

0.00

AnaptysBio Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
DeferredTaxAndRevenue	Get a 7-Day Free Trial															3.28	0.00	0.00	0.00	0.00

44GF Score

AnaptysBio Inc FRA:AN6

DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Frequently Asked Questions Learn more about DeferredTaxAndRevenue →

What does a DeferredTaxAndRevenue of €0.0 Mil mean?

AnaptysBio (FRA:AN6) has a DeferredTaxAndRevenue of €0.0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on AnaptysBio.

Is AnaptysBio's DeferredTaxAndRevenue too high?

AnaptysBio's current DeferredTaxAndRevenue is €0.0 Mil. Overall, AnaptysBio has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.

How does AnaptysBio's DeferredTaxAndRevenue compare to MLTX and ABCL?

AnaptysBio's DeferredTaxAndRevenue of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good DeferredTaxAndRevenue for a Biotechnology company?

A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high DeferredTaxAndRevenue mean?

A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on AnaptysBio. AnaptysBio's current DeferredTaxAndRevenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AnaptysBio stock overvalued right now?

AnaptysBio (FRA:AN6) has a current DeferredTaxAndRevenue of €0.0 Mil. The current DeferredTaxAndRevenue is €0.0 Mil. AnaptysBio's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is DeferredTaxAndRevenue calculated?

DeferredTaxAndRevenue is calculated from a company's financial statements. For AnaptysBio (FRA:AN6), the current DeferredTaxAndRevenue is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AnaptysBio Business Description

Industry Healthcare Biotechnology

Comparable Companies MLTX ABCL TSHA INVA RXRX SRPT MPLT MAZE ZYME NTLA VRTX REGN XBRU:ARGX XBRU:UCB XKRX:207940 RVMD ASX:CSL ALNY ONC XKRX:068270

Other Exchanges ANAB:USA 0HFQ:UK

Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121

Website https://www.anaptysbio.com

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

44GF Score

Get the complete analysis for FRA:AN6

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.27

Price

View FRA:AN6 Analysis

See DeferredTaxAndRevenue data for all stocks →